Commonwealth Equity Services’s HTG Molecular Diagnostics HTGM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
– Sell
-212
Closed -$12K – 3290
2020
Q3
$12K Buy
+212
New +$18.9K ﹤0.01% 3032
2019
Q4
– Sell
-56
Closed -$6K – 2965
2019
Q3
$6K Sell
56
-50
-47% -$10.1K ﹤0.01% 2830
2019
Q2
$31K Sell
106
-50
-32% -$20.9K ﹤0.01% 2721
2019
Q1
$70K Hold
156
– – ﹤0.01% 2642
2018
Q4
$71K Hold
156
– – ﹤0.01% 2535
2018
Q3
$141K Buy
156
+6
+4% +$3.96K ﹤0.01% 2590
2018
Q2
$88K Buy
150
+25
+20% +$16.3K ﹤0.01% 2615
2018
Q1
$81K Buy
125
+50
+67% +$37.5K ﹤0.01% 2561
2017
Q4
$27K Hold
75
– – ﹤0.01% 2608
2017
Q3
$23K Buy
+75
New +$28.5K ﹤0.01% 2522

Other funds holding HTGM

Commonwealth Equity Services's HTGM Position: Q4 2020 in Review

Commonwealth Equity Services sold out of HTG Molecular Diagnostics (HTGM) in Q4 2020, closing a stake of 212 shares — an estimated $12K sold.

Commonwealth Equity Services first reported a position in HTGM in Q3 2017 and held it in 10 quarters. The position peaked at $141K in Q3 2018. 23 funds tracked by Wall St. Rank hold HTGM as of Q4 2020.

  • Commonwealth Equity Services reported no remaining HTG Molecular Diagnostics position as of Q4 2020 after selling out during the quarter.
  • Commonwealth Equity Services sold 212 HTG Molecular Diagnostics shares in Q4 2020, an estimated $12K.
  • Commonwealth Equity Services first reported a position in HTG Molecular Diagnostics in Q3 2017 and held it in 10 quarters.
  • Commonwealth Equity Services's HTG Molecular Diagnostics position peaked at $141K in Q3 2018.
  • 23 funds tracked by Wall St. Rank held HTG Molecular Diagnostics as of Q4 2020.

Based on Commonwealth Equity Services's 13F filing for Q4 2020, filed 11 Feb 2021.